Curcusome-RA / UniQuest, J&J - LARVOL DELTA

A dendritic cell vaccine to suppress the immune response to citrullinated antigen in rheumatoid arthritis (ANZCTR) - P1 | N=18 | Completed | Sponsor: Uniquest | Active, not recruiting ➔ Completed

Trial completion • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • HLA-DRB1

Toward immune tolerance in rheumatoid arthritis: Emerging immunotherapies and targets for long-term remission. (PubMed, Int Immunopharmacol) - "Clinical trials, including Rheumavax and calcitriol liposomes, demonstrate safety and immunomodulatory promise, particularly in early RA. Programmed cell death-1 (PD-1) agonists, like rosnilimab, show potential in restoring immune homeostasis by reducing pathogenic T cell responses...Challenges include patient classification, biomarker detection, and long-term safety. These therapies represent a paradigm shift from broad immunosuppression to targeted immune reprogramming, offering hope for antigen-specific, drug-free remission in RA."

IO biomarker • Journal • Review • Immunology • Inflammatory Arthritis • Oncology • Rheumatoid Arthritis • Rheumatology • PD-1